O'Brien C
No ORCID on file
· 6 papers in corpus
· active 2013-2026
Study types
- article 3
Condition tags
- endometriosis 3
- chronic_pelvic_pain 2
- dysmenorrhea 1
- dyspareunia 1
Top journals
Frequent coauthors
- Jimenez R 3
- Bruce R. Carr 3
- Joshua Burke 3
- Jiang P 3
- Carr B 3
- Dmowski WP 3
- Chwalisz K 3
- Burke J 3
- Chris O’Brien 3
- Kristof Chwalisz 3
2026
The presence of uterine fibroids impacts fertility through multiple mechanisms. While subserosal fibroids have minimal impact, especially when of reduced size, the presence of intramural fibroids impacts both the likelihood of pregnancy and…
2025
Polycystic ovary syndrome (PCOS) is a systemic metabolic and endocrine disorder that significantly disrupts reproductive physiology and endometrial function. In this narrative review, we examine the molecular impact of metabolic and hormona…
2025
Glaucoma is a group of progressive optic neuropathies and the leading cause of irreversible vision loss worldwide. It is a chronic eye disease, and its major pathological features include fibrosis of the trabecular meshwork, Schlemm's Canal…
article
2014
This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mi…
article
2013
OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…
article
2013
This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg …